Research programme: botulinum toxin A therapeutics - Revance Therapeutics

Drug Profile

Research programme: botulinum toxin A therapeutics - Revance Therapeutics

Alternative Names: RT401

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Revance Therapeutics
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Rhinitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rhinitis in USA (Topical)
  • 02 Jun 2016 Revance Therapeutics acquires botulinum toxin patent portfolio from Botulinum Toxin Research Associates
  • 27 Oct 2010 Preclinical trials in Rhinitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top